Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1961 2
1963 1
1973 3
1974 1
1975 1
1976 1
1977 3
1978 4
1979 2
1980 2
1981 2
1982 3
1984 5
1985 8
1986 9
1987 5
1988 11
1989 10
1990 16
1991 19
1992 14
1993 13
1994 11
1995 16
1996 23
1997 10
1998 21
1999 22
2000 15
2001 25
2002 14
2003 21
2004 10
2005 17
2006 20
2007 22
2008 21
2009 23
2010 29
2011 31
2012 29
2013 29
2014 32
2015 42
2016 38
2017 26
2018 36
2019 26
2020 38
2021 38
2022 41
2023 21

Text availability

Article attribute

Article type

Publication date

Search Results

796 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: mukai h. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Adams S, et al. Among authors: mukai h. Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518. Ann Oncol. 2019. PMID: 30475947 Free article. Clinical Trial.
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M. Im SA, et al. Among authors: mukai h. J Glob Oncol. 2019 May;5:1-19. doi: 10.1200/JGO.18.00173. J Glob Oncol. 2019. PMID: 31125276 Free PMC article. Clinical Trial.
Segmental neurofibromatosis.
Niiyama S, Satoh K, Kaneko S, Aiba S, Mukai H. Niiyama S, et al. Among authors: mukai h. Acta Derm Venereol. 2005;85(5):448-9. doi: 10.1080/00015550510033165. Acta Derm Venereol. 2005. PMID: 16159742 Free article. No abstract available.
Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability.
Kamiya M, Matsumoto M, Yamashita K, Izumi T, Kawaguchi M, Mizukami S, Tsurumaru M, Mukai H, Kawakami S. Kamiya M, et al. Among authors: mukai h. Pharmaceutics. 2022 Oct 31;14(11):2357. doi: 10.3390/pharmaceutics14112357. Pharmaceutics. 2022. PMID: 36365175 Free PMC article.
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, Hozumi Y, Hasegawa Y, Yanagita Y, Takei H, Tanaka M, Masuoka H, Tanabe M, Egawa C, Komoike Y, Nakamura T, Ohtsu H, Mukai H. Iwase T, et al. Among authors: mukai h. J Clin Oncol. 2023 Jun 20;41(18):3329-3338. doi: 10.1200/JCO.22.00577. Epub 2023 Apr 20. J Clin Oncol. 2023. PMID: 37079878 Clinical Trial.
796 results